CK2 and ERK8 Inhibitor: Mechanism and Research Benchmarks

Executive Summary: The CK2 and ERK8 inhibitor B7464 is a chemically defined small molecule with a molecular weight of 534.82 and specific solubility in DMSO under 13.37 mg/ml (product information). It is used to selectively inhibit protein kinases CK2 and ERK8, which govern cell cycle and apoptosis signaling (reference study). The compound is structurally a tetrabromo benzimidazole derivative, offering high specificity for kinase-related biochemical assays. Its purity exceeds 98.00%, ensuring reproducibility in research use only chemical applications. APExBIO supplies this inhibitor, complete with quality documentation and safe shipping protocols.

Biological Rationale

Protein kinases CK2 and ERK8 are central regulators of intracellular signaling. CK2 (Casein Kinase 2) participates in more than 300 phosphorylation events affecting gene expression, cell proliferation, and apoptosis. ERK8 (Extracellular signal-Regulated Kinase 8) modulates stress responses and cell cycle checkpoints. Dysregulation of these kinases is implicated in oncogenesis, antiviral responses, and protein phase separation processes. Targeting these enzymes with a small molecule inhibitor enables precise interrogation of phosphorylation-dependent mechanisms in both normal and disease states (Translational Frontiers: Leveraging TMCB… extends prior mechanistic reviews by focusing on translational use cases).

Mechanism of Action of CK2 and ERK8 inhibitor

The CK2 and ERK8 inhibitor (2-(4,5,6,7-tetrabromo-2-(dimethylamino)-1H-benzo[d]imidazol-1-yl)acetic acid) is a tetrabromo benzimidazole derivative designed to block ATP binding sites on CK2 and ERK8 enzymes. By occupying these sites, the inhibitor prevents substrate phosphorylation, resulting in modulation of downstream cellular signaling cascades. Inhibition of CK2 reduces phosphorylation of nuclear and cytoplasmic proteins, impacting cell survival and division. Suppression of ERK8 activity perturbs the MAPK pathway, which is essential for managing cellular stress and protein–RNA interactions. This dual inhibition makes the compound an effective molecular tool for enzyme interaction, protein interaction studies, and condensate biology (Molecular Insights into Enz... offers detailed molecular context which this article extends to phase separation applications).

Evidence & Benchmarks

• High-purity formulation (≥98.00% by COA), suitable for reproducible kinase inhibition assays (product information).
• Demonstrated DMSO solubility up to 13.37 mg/ml at room temperature, enabling flexible dosing in biochemical protocols (product information).
• Stability is maintained for the solid form at room temperature; solution form should be freshly prepared for optimal efficacy (product information).
• Tetrabromo benzimidazole derivatives have been shown to modulate protein–RNA phase separation, a mechanism relevant to viral nucleocapsid assembly and immune evasion (Nature Communications, 2021).
• Research use only; not intended for diagnostic or therapeutic applications (product information).
• Provides reliable modulation of kinase activity for protein condensate studies, as summarized in comparative benchmarking (Applied Use of 2-(4,5,6,7-tetrabromo...) updates troubleshooting and protocol guidance).

Applications, Limits & Misconceptions

This small molecule serves as a chemical probe for biochemical research, particularly in kinase signaling and condensate biology. Typical use cases include:

• Biochemical reagent for protein interaction studies.
• Molecular tool for enzyme interaction and kinase pathway dissection.
• Investigation of protein–RNA phase separation and its modulation in viral and cellular contexts.
• Workflow-ready for in vitro kinase assays and cellular signaling models.

However, the compound is not a therapeutic agent and must not be used for in vivo diagnostics or patient treatment. Its specificity is limited to CK2 and ERK8 within tested concentration ranges; off-target effects at supra-physiological doses have not been fully characterized. The inhibitor’s effectiveness in phase separation modulation is inferred from structural analog studies; direct evidence in all contexts may vary.

Common Pitfalls or Misconceptions

• Assuming the compound is suitable for in vivo or clinical use—APExBIO explicitly restricts it to research applications.
• Presuming broad kinase inhibition—selectivity is limited and should be experimentally confirmed for each system.
• Long-term storage of dissolved compound—efficacy is compromised; prepare fresh aliquots as needed.
• Using at concentrations above DMSO solubility limits—risk of precipitation or assay interference.
• Equating all tetrabromo benzimidazole derivatives—structural analogs may differ significantly in potency or selectivity.

Workflow Integration & Parameters

• Compound Preparation: Dissolve the inhibitor in DMSO at concentrations below 13.37 mg/ml; avoid aqueous buffers to prevent precipitation (product information).
• Storage: Store solid at room temperature; avoid prolonged storage of solutions to maintain purity and functional integrity.
• Experimental Controls: Include vehicle-only and non-target kinase controls to interpret specificity.
• Recommended Use: Apply as a molecular tool for enzyme interaction or biochemical reagent for protein interaction studies, particularly in kinase assays and condensate biology workflows (Redefining Condensate Biology… expands on workflow integration for condensate analysis).
• Shipping: Product ships with blue ice for temperature stability during transit.

Conclusion & Outlook

The CK2 and ERK8 inhibitor (B7464) offers a high-purity, well-characterized, and workflow-ready solution for kinase pathway and condensate biology research. Its chemical attributes—tetrabromo benzimidazole core, DMSO solubility, and dual kinase specificity—make it a valuable research use only chemical for cellular and biochemical experiments. Recent studies, such as the disruption of viral nucleocapsid phase separation by small molecules, highlight the translational potential of this chemical class (Nature Communications, 2021). Ongoing work will clarify the broader implications for antiviral research and enzyme modulation, but users must adhere to recommended protocols and recognize its limitations for clinical use. For further mechanistic and troubleshooting guidance, see Expanding Applications of TMCB…, which this article updates with specific protocol and evidence-based boundaries.